Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (261-270 of 484) with videos related to

Pageof 49
Sort By:
Cancer Research|April 19, 2006
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridizationSapna Vijayakumar, Devon C Hall, Xavier T Reveles, et al.
Prostate Cancer and Prostatic Diseases|November 3, 2018
Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR studyMichael A Liss, Osamah Al-Bayati, Jonathan Gelfond, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
Urologic Oncology|July 31, 2004
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncologyWilliam E Grizzle, O John Semmes, Joseph Basler, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.
The Journal of Urology|January 27, 2009
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialIan M Thompson, Catherine M Tangen, Jorge Paradelo, et al.
The Journal of Urology|October 24, 2002
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109Isaac J Powell, Catherine M Tangen, Gary J Miller, et al.
JAMA Network Open|August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 TrialNicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
BMC Urology|March 30, 2022
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trialsJonathan A Gelfond, Brian Hernandez, Martin Goros, et al.
Pageof 49

Showing results (261-270 of 484) with videos related to

Sort By:
Pageof 49
Cancer Research|April 19, 2006
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridizationSapna Vijayakumar, Devon C Hall, Xavier T Reveles, et al.
Prostate Cancer and Prostatic Diseases|November 3, 2018
Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR studyMichael A Liss, Osamah Al-Bayati, Jonathan Gelfond, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw W Twardowski, Catherine M Tangen, Xiwei Wu, et al.
Urologic Oncology|July 31, 2004
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncologyWilliam E Grizzle, O John Semmes, Joseph Basler, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.
The Journal of Urology|January 27, 2009
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialIan M Thompson, Catherine M Tangen, Jorge Paradelo, et al.
The Journal of Urology|October 24, 2002
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109Isaac J Powell, Catherine M Tangen, Gary J Miller, et al.
JAMA Network Open|August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 TrialNicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
BMC Urology|March 30, 2022
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trialsJonathan A Gelfond, Brian Hernandez, Martin Goros, et al.
Pageof 49